ANXA4 has been implicated in several cancers, and the current results suggest that therapy targeting ANXA4 may suppress the NF-κB signaling pathway, further reversing ANXA4 overexpression in a feedback regulatory mechanism and resulting in inhibition of tumor growth. Here, NFKB1 is linked to neoplasm.